A peptide and longevity newsletter that mixes playful fictional framing (a professor's classroom turned police precinct) with fact-checked summaries of clinical trials, such as teriparatide fracture data and retatrutide dose-response results. It aims to separate solid peptide evidence from hype and bad science.
Website: https://m1bear.substack.com
Weekly explainers on peptide and related small-molecule research, focused on how to read studies critically and separate what evidence establishes from what it only suggests. Issues cover topics such as 9-Me-BC and dopamine, peptide combinations, and reading trials and dilution math.
A compliance newsletter for peptide and wellness business operators that uses enforcement data and case studies to show what regulatory failure costs. It argues for proactive compliance spending over remediation, with figures drawn from FDA warning letters and pharma fines.
Peptide Maven publishes explainers on peptides such as GLP-1, BPC-157 and Thymosin Alpha-1, covering research findings, regulatory changes and lifestyle strategies. Readers get research-framed summaries with TL;DRs, and a free peptide research and safety handbook on signup.
A newsletter explaining peptides, longevity medicine and proactive health with an Australian legal and regulatory focus. It warns about buying research-labelled peptides online and walks through the growth hormone axis, though each issue ends by promoting a clinic's prescription pathway.
One short email a week with hand-picked newsletters from the index. Free, no spam, unsubscribe anytime.
